Metabolite identification of a new tyrosine kinase inhibitor, HM781-36B, and a pharmacokinetic study by liquid chromatography/tandem mass spectrometry-Reference-Cited by-同舟云学术

Metabolite identification of a new tyrosine kinase inhibitor, HM781-36B, and a pharmacokinetic study by liquid chromatography/tandem mass spectrometry

Published:2013-04-24 Issue:11 Volume:27 Page:1183-1195
ISSN:0951-4198
Container-title:Rapid Communications in Mass Spectrometry
language:en
Short-container-title:Rapid Commun. Mass Spectrom.

Author:

Kim Eunyoung¹²,Kim Hankyong¹³,Suh Kweehyun¹,Kwon Sechang¹,Lee Gwansun¹,Park Na Hyun²,Hong Jongki²

Affiliation:

1. Department of Analysis, Hanmi Research Center; Hwaseong 445-813 Korea

2. College of Pharmacy; Kyung Hee University; Seoul 130-701 Korea

3. College of Pharmacy; Sungkyunkwan University; Suwon 440-746 Korea

Publisher

Wiley

Subject

Organic Chemistry,Spectroscopy,Analytical Chemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/rcm.6559/fullpdf

Reference23 articles.

1. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic;Nam;Cancer Lett.,2011

2. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models;Cha;Int. J. Cancer.,2012

3. In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites;Cai;Drug Metab. Dispos.,2007

4. Metabolism of a new P-glycoprotein inhibitor HM-30181 in rats using liquid chromatography/electrospray mass spectrometry;Paek;Rapid Commun. Mass Spectrom.,2006

5. Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers;Marull;J. Mass Spectrom.,2006

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS;Thoracic Cancer;2023-03-27

2. Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo;Pharmaceutical Biology;2023-02-02

3. Targeting exon 20 insertion mutations in lung cancer;Current Opinion in Oncology;2022-11-15

4. Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer;Expert Review of Anticancer Therapy;2021-12-28

5. Breast Cancer Treatments: Updates and New Challenges;Journal of Personalized Medicine;2021-08-19